EXHIBIT 99.1

                INTERLEUKIN GENETICS ANNOUNCES INTERIM FINANCING

Waltham, Mass. - October 24, 2002 -- Interleukin Genetics, Inc. (NASDAQ:ILGN)
announced today that it has entered into an agreement for interim financing of
up to $1.5 million from the same consumer products company with which the
Company has an outstanding Letter of Intent per the press release on September
3, 2002. The financing is in the form of three $500,000 promissory notes to be
issued and sold by the company, the first of which has already been closed. The
final closing is at the option of the consumer products company. With this
latest financing, the Company expects to have sufficient cash to meet its
operating requirements through January 2003. Interleukin Genetics is continuing
negotiations with that same consumer products company towards a definitive
strategic alliance and is seeking further financing from other third parties to
fund its operations through 2003 and beyond.

"This additional round of interim financing strengthens both the position of
Interleukin Genetics to continue our basic science research and clinical studies
and our relationship with this potential strategic partner," said Philip R.
Reilly, CEO of Interleukin Genetics. Reilly adds, "On-going discussions with
this company and other interested organizations reinforces our confidence in the
Company's long-term outlook."

ABOUT INTERLEUKIN GENETICS

Interleukin Genetics is a biotechnology company focused on inflammation. The
company uses functional genomics to develop diagnostic, therapeutic and
nutraceutical products based on the genetic variations in people to help prevent
or treat diseases of inflammation. Interleukin's TARxGET (Translating Advanced
Research in Genomics into more Effective Therapeutics) programs focus on the
areas of cardiovascular disease, rheumatoid arthritis and osteoporosis and
include the development of tests to assess a person's risk for heart disease and
osteoporosis as well as a test to help doctors and patients choose the best
course of therapy for rheumatoid arthritis. These products will improve patient
care and produce better allocation of healthcare resources. In addition to its
research partnerships with numerous academic centers in the U.S. and Europe,
Interleukin's corporate collaborators include the leading healthcare
organizations, Kaiser Permanente and UnitedHealth Group. For more information
about Interleukin and its ongoing programs, please visit
http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995)
including statements regarding the expectations about our future growth and
operating results, our ability to develop and commercialize our products,
entering into one or more strategic alliances on favorable terms with
well-funded partner, the sufficiency of the proceeds from our interim financing
to fund operations through January 2003, our efforts to obtain additional
financing through 2003 and our ability to remain listed on the NASDAQ SmallCap
Market or begin trading on the OTC Bulletin Board. Because such statements
include risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Factors that could
cause actual results to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to, possible
delisting of our common stock from the NASDAQ SmallCap market, our ability to
raise necessary capital, complete clinical research and data analysis, meet
expectations about operating through January 2003 with the proceeds from the
interim financing, meet clinical studies' endpoints, complete one or more
strategic alliances, risk of market acceptance of our products, risk of
technology and products obsolescence, delays in development of products,
reliance on partners, competitive risks and those risks and uncertainties
described in our Form 10-Q for the quarter ended June 30, 2002, as filed on
August 19, 2002, and in other filings we have made with Securities and Exchange
Commission. We disclaim any obligation to update these forward-looking
statements.

For Interleukin Genetics:

Sharon Leibowitz
Interleukin Genetics, Inc.
(781) 398-0700


# # #